Literature DB >> 19015646

Rilonacept in cryopyrin-associated periodic syndromes: the beginning of longer-acting interleukin-1 antagonism.

Leigh D Church1, Michael F McDermott.   

Abstract

Year:  2008        PMID： 19015646     DOI： 10.1038/ncprheum0959

Source DB:  PubMed          Journal:  Nat Clin Pract Rheumatol        ISSN： 1745-8382


× No keyword cloud information.
  8 in total

1.  Interleukin-1-receptor antagonist in the Muckle-Wells syndrome.

Authors:  Philip N Hawkins; Helen J Lachmann; Michael F McDermott
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

2.  A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome.

Authors:  Raphaela Goldbach-Mansky; Sharukh D Shroff; Mildred Wilson; Christopher Snyder; Sara Plehn; Beverly Barham; Tuyet-Hang Pham; Frank Pucino; Robert A Wesley; Joanne H Papadopoulos; Steven P Weinstein; Scott J Mellis; Daniel L Kastner
Journal:  Arthritis Rheum       Date:  2008-08

3.  IL-1 trap go-ahead.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2008-05       Impact factor: 54.908

4.  Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors:  Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal:  Arthritis Rheum       Date:  2008-08

Review 5.  Primer: inflammasomes and interleukin 1beta in inflammatory disorders.

Authors:  Leigh D Church; Graham P Cook; Michael F McDermott
Journal:  Nat Clin Pract Rheumatol       Date:  2008-01

Review 6.  Anti-cytokines and cytokines in the treatment of rheumatoid arthritis.

Authors:  Peter C Taylor
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

7.  Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade.

Authors:  Maya H Buch; Sarah J Bingham; Yohei Seto; Dennis McGonagle; Victoria Bejarano; Jo White; Paul Emery
Journal:  Arthritis Rheum       Date:  2004-03

8.  Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist.

Authors:  Hal M Hoffman; Sanna Rosengren; David L Boyle; Jae Y Cho; Jyothi Nayar; James L Mueller; Justin P Anderson; Alan A Wanderer; Gary S Firestein
Journal:  Lancet       Date:  2004 Nov 13-19       Impact factor: 79.321
  8 in total
  6 in total

Review 1.  Inflammasomes in the pathophysiology of autoinflammatory syndromes.

Authors:  Sarang Tartey; Thirumala-Devi Kanneganti
Journal:  J Leukoc Biol       Date:  2019-10-14       Impact factor: 4.962

Review 2.  Update on biology: uric acid and the activation of immune and inflammatory cells.

Authors:  Fabio Martinon
Journal:  Curr Rheumatol Rep       Date:  2010-04       Impact factor: 4.592

Review 3.  Inflammasome activation in obesity-related inflammatory diseases and autoimmunity.

Authors:  John R Lukens; Vishwa Deep Dixit; Thirumala-Devi Kanneganti
Journal:  Discov Med       Date:  2011-07       Impact factor: 2.970

Review 4.  Interleukin-1 function and role in rheumatic disease.

Authors:  Georg Schett; Jean-Michel Dayer; Bernhard Manger
Journal:  Nat Rev Rheumatol       Date:  2015-12-10       Impact factor: 20.543

5.  IL-1 family cytokines trigger sterile inflammatory disease.

Authors:  John R Lukens; Jordan M Gross; Thirumala-Devi Kanneganti
Journal:  Front Immunol       Date:  2012-10-09       Impact factor: 7.561

6.  Single-Chain Soluble Receptor Fusion Proteins as Versatile Cytokine Inhibitors.

Authors:  Aurora Holgado; Harald Braun; Kenneth Verstraete; Domien Vanneste; Nico Callewaert; Savvas N Savvides; Inna S Afonina; Rudi Beyaert
Journal:  Front Immunol       Date:  2020-07-13       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.